Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB: TRUFF) reported new clinical activity for its wholly owned subsidiary Filament Health’s botanical psilocybin candidate PEX010 following Filament’s acquisition.
PEX010 shipments now support Canadian academic studies in palliative care (Phase I/II and planned Phase 3), bipolar II treatment-resistant depression, and healthy adult mechanism research, while backing over 70 research studies worldwide and a 76‑patent portfolio.
Red Light Holland (CSE: TRIP, OTCQB: TRUFF) shareholders overwhelmingly approved a proposed corporate name change at the May 11, 2026 annual general and special meeting. Shareholders also approved auditor re-appointment, a share consolidation, and elected all nominated directors. The company announced CFO Keith Li's planned resignation and settled $735,874.22 of debt via issuing 18,396,855 common shares at $0.04 per share.
Red Light Holland (OTCQB: TRUFF) highlighted a JAMA Network Open randomized trial (published May 7, 2026) reporting a single synthetic dose of psilocybin reduced cocaine use versus active placebo through six months.
Filament Health holds an exclusive worldwide license to the trial data/IP and has Phase 2 authorization from the FDA and Health Canada for its botanical candidate PEX010.
Red Light Holland (OTCQB: TRUFF) confirmed expanded distribution of Filament Health's botanical psilocybin drug candidate PEX010 across Canadian and U.S. research institutions and compassionate use patients.
Highlights include repeat shipments to University of Calgary and UCSF, a first-time Canadian academic shipment, multiple compassionate-use deliveries, third-party lab testing support, and completion of Red Light's April 30, 2026 acquisition of Filament with 76 issued patents.
Red Light Holland (OTCQB: TRUFF) announced an intended corporate rebrand following the closing of the Filament Health acquisition and said a new name will be proposed at the Annual General and Special Meeting on May 11, 2026.
The combined company adds GMP manufacturing, FDA-aligned drug development capabilities and a lead botanical psilocybin candidate, PEX010, currently evaluated at >70 clinical research sites. Management urged shareholders to vote IN FAVOUR of the name-change resolution; details will be in the management information circular.
Red Light Holland (OTCQB: TRUFF) completed its acquisition of Filament Health effective April 29, 2026, creating a vertically integrated psychedelic platform combining Filament's pharmaceutical-grade R&D, a Health Canada Dealer's License, and a portfolio of 70+ patents with Red Light's global distribution.
The transaction issued 99,180,497 consideration shares plus 70,836,683 shares for debt settlement, leaving 595,727,901 Red Light shares outstanding and former Filament holders owning approximately 30%.
Red Light Holland (OTCQB: TRUFF) and Filament Health (OTC: FLHLF) announced that the Supreme Court of British Columbia issued a final order approving Red Light's planned acquisition of all issued and outstanding common shares of Filament under a statutory plan of arrangement.
Completion remains subject to customary conditions and certain regulatory approvals and is anticipated on or about April 29, 2026 under the arrangement agreement dated March 10, 2026. Further details are available in Filament's management information circular and on SEDAR+.
Red Light Holland (OTCQB: TRUFF) announced that Filament Health shareholders approved a plan of arrangement on April 24, 2026, enabling Red Light to acquire all issued Filament shares.
Key facts: 196,282,175 votes (≈99.99%) supported the arrangement; up to 182,447,452 Consideration Shares are issuable; Filament holders expected to own ≈30% post-close. Closing remains subject to court approval and customary conditions, with an expected close on or about April 29, 2026. Resale restrictions release 50% at six months, 25% at nine months and 25% at twelve months.
Red Light Holland (OTCQB: TRUFF) reports continued clinical shipments of Filament Health's botanical psilocybin drug candidate PEX010 to Canadian universities, including second shipments to University of Calgary and first-time shipments to University of British Columbia and additional UCalgary studies.
The company cites growing demand for pharmaceutical-grade natural psilocybin and notes a definitive arrangement agreement to acquire Filament Health, with an interim Supreme Court of British Columbia order issued March 23, 2026; closing remains subject to shareholder and final court approval and other customary conditions.
Red Light Holland (OTCQB:TRUFF) highlighted an FDA IND–authorized Phase 1 study led at the University of Washington showing that a second psilocybin session produced sustained psychological benefits in metastatic cancer patients.
Key data: mean HADS fell from 15.08 to 9.00 after the second session, 69% of participants dropped below clinical anxiety/depression thresholds, and reports of complete mystical experience rose from 38% to 77%. No serious adverse events reported. Filament's PEX010 now supplied to 70+ clinical sites worldwide. Red Light is promoting this evidence amid its proposed acquisition of Filament and evolving U.S. policy support for psychedelic research.